A promising antimicrobial hit is only the start. The harder questions are whether activity holds across strains and conditions, what biology underlies the respon...

In 2026, setting clear AI expectations is the priority. On January 14, 2026, EMA and FDA marked a step towards regulatory alignment by publishing joint guiding p...

Bringing candidate drugs to market quickly and cost-effectively and pinpointing and eliminating failures from drug development pathways early helps to reduce cos...

Biosimilars were expected to widen access to biologic medicines by introducing competition into some of the most expensive areas of therapy. In many parts of the...

The biologics sector has moved from a specialist segment to one of the most dynamic areas in pharmaceutical manufacturing. Recent market estimates place the biol...

To consistently reproduce high-quality biologics across operations, technology transfer in new environments requires disciplined coordination across development,...

Psychiatry has spent a century trying to treat what it could not see. Patient-derived neurons are about to change that. Depression touches a staggering portio...

Mental health diagnostics have been in crisis for some time now due to increasing patient loads, lack of definitive diagnostics and adverse societal impact. This...

Standard of care treatments for neurological disorders like Parkinson’s still rely on therapeutic principles established over 50 years ago,12 and these treatment...

Ninety per cent of drug candidates that enter clinical trials never reach patients. Developing a single new medicine now costs more than a billion dollars. Too o...